UK markets closed
  • FTSE 100

    -2.26 (-0.03%)
  • FTSE 250

    -46.14 (-0.24%)
  • AIM

    +2.76 (+0.32%)

    +0.0013 (+0.11%)

    +0.0040 (+0.33%)

    -68.70 (-0.50%)
  • CMC Crypto 200

    +2.91 (+0.72%)
  • S&P 500

    -4.87 (-0.12%)
  • DOW

    +34.87 (+0.10%)

    -0.88 (-1.08%)

    -3.80 (-0.21%)
  • NIKKEI 225

    -448.18 (-1.59%)

    -61.09 (-0.33%)
  • DAX

    +39.09 (+0.27%)
  • CAC 40

    -11.72 (-0.17%)

Global Synthetic Small Molecule API Market Report 2022: Featuring Merck, Viatris, Cipla, Teva, Sun Pharmaceuticals & More

Company Logo
Company Logo



Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Synthetic Small Molecule API Market Size, Share & Industry Trends Analysis Report by Manufacturer, Application, Regional Outlook and Forecast, 2022-2028" report has been added to's offering.

The Global Synthetic Small Molecule API Market size is expected to reach $187.8 billion by 2028, rising at a market growth of 5.4% CAGR during the forecast period.

Although their component monomers (amino acids, ribo or deoxyribonucleotides, and monosaccharides, respectively) are frequently regarded as small molecules, larger structures like nucleic acids, proteins, and many polysaccharides are not small molecules. Small molecules can be employed as research tools to examine biological processes and as a source of inspiration for the creation of novel therapeutics.

Some can prevent a protein from performing a certain function or interfere with protein-protein interactions. The term 'small molecule' is typically used in pharmacology to refer to molecules that bind to particular biological macromolecules and work as an effector to change the activity or serve of the target. Small molecules can be used biologically for a wide range of purposes, including as medications, insecticides, cell signaling molecules, and many other things. These substances may be synthetic (like antiviral medications) or natural (like secondary metabolites), and they may be advantageous or harmful in the fight against the disease.

A tiny molecule can have a maximum molecular weight of about 900 Daltons, which enables it to swiftly diffuse across a cellular membrane and reach intracellular areas of action. This molecular weight cutoff enables transcellular transport through intestinal epithelial cells, which is another necessary but inadequate criterion for oral bioavailability. In addition to intestinal permeability, the chemical must also have a moderate to low first-pass metabolism, a moderately quick rate of dissolution into water, and appropriate water solubility.

Market Growth Factors

Increasing Use of Personalized Medicine

The aforementioned technological developments are also giving researchers a better understanding of the unique characteristics of smaller groups of disorders that were previously thought to be prevalent in all patients. For instance, the effect of particular genetic alterations on how responsively various tumors respond to various types of therapy is now more understood.

The rates of cardiovascular, cancer and infectious diseases are rising alarmingly

The healthcare industry's technological improvements present this market with enormous growth potential. More R&D is made possible by the expansion of the healthcare infrastructure. Small molecule API will be used increasingly frequently as medication development research accelerates. The powers of small molecule pharma will also be revealed. Businesses that offer small molecule API will have more prospects in the years to come.

Market Restraining Factors
Lack of Trained and Skilled Medical Personnel

The shortage of competent and qualified healthcare personnel is one of the reasons that is expected to restrict the growth of the small molecule API market. The market's expansion is also expected to be hampered by the high price of small molecule API, a lack of pathologists, a lack of a compensation scheme, and a large initial investment. In the field of interventional oncology, equipment and techniques are constantly being refined to increase their accuracy and specificity. However, only full-time professionals can attain and keep excellent standards for a method like interventional oncology.

Scope of the Study

Market Segments Covered in the Report:
By Manufacturer

  • In-house

  • Outsourced

By Application

  • Cardiology

  • Oncology

  • CNS & Neurology

  • Endocrinology

  • Orthopedic

  • Gastroenterology

  • Pulmonology

  • Nephrology

  • Ophthalmology

  • Others

By Geography

  • North America

  • US

  • Canada

  • Mexico

  • Rest of North America

  • Europe

  • Germany

  • UK

  • France

  • Russia

  • Spain

  • Italy

  • Rest of Europe

  • Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Singapore

  • Malaysia

  • Rest of Asia Pacific


  • Brazil

  • Argentina

  • UAE

  • Saudi Arabia

  • South Africa

  • Nigeria

  • Rest of LAMEA

Key Market Players
List of Companies Profiled in the Report:

  • Merck & Co., Inc.

  • Viatris, Inc.

  • Cipla Limited

  • Teva Pharmaceuticals Industries Ltd.

  • Sun Pharmaceuticals Industries Ltd.

  • AbbVie, Inc.

  • Bristol Myers Squibb Company

  • Boehringer Ingelheim International GmbH

  • Aurobindo Pharma Limited

  • Albermale Corporation

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Global Synthetic Small Molecule API Market by Manufacturer

Chapter 4. Global Synthetic Small Molecule API Market by Application

Chapter 5. Global Synthetic Small Molecule API Market by Region

Chapter 6. Company Profiles

For more information about this report visit


CONTACT: CONTACT: Laura Wood,Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900